{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:17:38Z","timestamp":1792628258070,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40263-021-00832-x","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T02:02:39Z","timestamp":1625796159000},"page":"703-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively"],"prefix":"10.1007","volume":"35","author":[{"given":"Samuel R.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3343-0907","authenticated-orcid":false,"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"832_CR1","first-page":"129","volume":"8","author":"HP Loomer","year":"1957","unstructured":"Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep. 1957;8:129\u201341.","journal-title":"Psychiatr Res Rep"},{"key":"832_CR2","unstructured":"National Institute for Health and Care Excellence. Depression in adults: recognition and management. In: Clinical guidelines CG90. 2009."},{"issue":"5","key":"832_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881115581093","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459\u2013525.","journal-title":"J Psychopharmacol"},{"issue":"Suppl 10","key":"832_CR4","first-page":"9","volume":"167","author":"A Gelenberg","year":"2010","unstructured":"Gelenberg A, et al. American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder. Am J Psychiatry. 2010;167(Suppl 10):9\u2013118.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"832_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0706743716659417","volume":"61","author":"SH Kennedy","year":"2016","unstructured":"Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540\u201360.","journal-title":"Can J Psychiatry"},{"key":"832_CR6","doi-asserted-by":"crossref","unstructured":"Corrigendum to\u00a0Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540\u2013560. Can J Psychiatry. 2017;62(5):356\u2013356.","DOI":"10.1177\/0706743716659417"},{"issue":"12","key":"832_CR7","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/0004867415617657","volume":"49","author":"GS Malhi","year":"2015","unstructured":"Malhi GS, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087\u2013206.","journal-title":"Aust N Z J Psychiatry"},{"issue":"12","key":"832_CR8","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.euroneuro.2016.10.005","volume":"26","author":"M Dold","year":"2016","unstructured":"Dold M, et al. Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers\u2014a pharmacoepidemiological cross-sectional multicenter study. Eur Neuropsychopharmacol. 2016;26(12):1960\u201371.","journal-title":"Eur Neuropsychopharmacol"},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"204512532093049","DOI":"10.1177\/2045125320930492","volume":"10","author":"C Paton","year":"2020","unstructured":"Paton C, et al. Prescribing for moderate or severe unipolar depression in patients under the long-term care of UK adult mental health services. Ther Adv Psychopharmacol. 2020;10:2045125320930492.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"4","key":"832_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/1039856216634824","volume":"24","author":"D Menkes","year":"2016","unstructured":"Menkes D, Bosanac P, Castle D. MAOIs\u2014does the evidence warrant their resurrection? Australas Psychiatry. 2016;24(4):371\u20133.","journal-title":"Australas Psychiatry"},{"issue":"10","key":"832_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40263-013-0097-3","volume":"27","author":"KI Shulman","year":"2013","unstructured":"Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013;27(10):789\u201397.","journal-title":"CNS Drugs"},{"issue":"3","key":"832_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000117841","volume":"7","author":"D Raft","year":"1981","unstructured":"Raft D, et al. Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo. Neuropsychobiology. 1981;7(3):122\u20136.","journal-title":"Neuropsychobiology"},{"issue":"10","key":"832_CR13","first-page":"755","volume":"22","author":"TG Cant\u00fa","year":"1988","unstructured":"Cant\u00fa TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm. 1988;22(10):755\u20139.","journal-title":"Drug Intell Clin Pharm"},{"issue":"3","key":"832_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0893-133X(94)00058-8","volume":"12","author":"ME Thase","year":"1995","unstructured":"Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185\u2013219.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"832_CR15","doi-asserted-by":"publisher","first-page":"e0153380","DOI":"10.1371\/journal.pone.0153380","volume":"11","author":"R Meister","year":"2016","unstructured":"Meister R, et al. Comparative safety of pharmacologic treatments for persistent depressive disorder: a systematic review and network meta-analysis. PLoS ONE. 2016;11(5):e0153380.","journal-title":"PLoS ONE"},{"issue":"5","key":"832_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403\u201339.","journal-title":"J Psychopharmacol"},{"issue":"5204","key":"832_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/bmj.2.5204.1019","volume":"2","author":"G Davies","year":"1960","unstructured":"Davies G. Side-effects of phenelzine. BMJ. 1960;2(5204):1019.","journal-title":"BMJ"},{"issue":"5449","key":"832_CR18","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/bmj.1.5449.1554-b","volume":"1","author":"I MacLeod","year":"1965","unstructured":"MacLeod I. Fatal reaction to phenelzine. BMJ. 1965;1(5449):1554.","journal-title":"BMJ"},{"issue":"1","key":"832_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00004714-198502000-00002","volume":"5","author":"JG Rabkin","year":"1985","unstructured":"Rabkin JG, et al. Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. J Clin Psychopharmacol. 1985;5(1):2\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"832_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00004714-198408000-00013","volume":"4","author":"JW Stewart","year":"1984","unstructured":"Stewart JW, et al. Phenelzine-induced pyridoxine deficiency. J Clin Psychopharmacol. 1984;4(4):225\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"832_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euroneuro.2017.05.007","volume":"27","author":"S Ulrich","year":"2017","unstructured":"Ulrich S, Ricken R, Adli M. Tranylcypromine in mind (Part I): review of pharmacology. Eur Neuropsychopharmacol. 2017;27(8):697\u2013713.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"832_CR22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euroneuro.2017.04.003","volume":"27","author":"R Ricken","year":"2017","unstructured":"Ricken R, et al. Tranylcypromine in mind (Part II): review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714\u201331.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"832_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1176\/ajp.2006.163.9.1531","volume":"163","author":"PJ McGrath","year":"2006","unstructured":"McGrath PJ, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR* D report. Am J Psychiatry. 2006;163(9):1531\u201341.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"832_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1192\/bjp.146.6.576","volume":"146","author":"C Pare","year":"1985","unstructured":"Pare C. The present status of monoamine oxidase inhibitors. Br J Psychiatry. 1985;146(6):576\u201384.","journal-title":"Br J Psychiatry"},{"key":"832_CR25","unstructured":"Baldessarini R. Drugs and the treatment of psychiatric disorders; psychosis and anxiety. In: Goodman & Gilman's: The pharmacological basis of therapeutics.  McGraw Hill, New York; 1996. pp. 399\u2013430."},{"key":"832_CR26","unstructured":"Haase HJ, Buhr HJ. Untersuchungen zur vertraeglichkeit des antidepressivums jatrosom. Med Welt Dtsch Da. 1973;6:221\u20134."},{"issue":"6","key":"832_CR27","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1600-0447.1991.tb03196.x","volume":"84","author":"J Larsen","year":"1991","unstructured":"Larsen J, et al. Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. Acta Psychiatr Scand. 1991;84(6):564\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"832_CR28","doi-asserted-by":"crossref","unstructured":"Larsen JK, Krogh-Nielsen L, Br\u00f8sen K. The monoamine oxidase inhibitor isocarboxazid is a relevant treatment option in treatment-resistant depression-experience-based strategies in Danish psychiatry. Health Care Curr Rev. 2016:1\u20134.","DOI":"10.4172\/2375-4273.1000168"},{"issue":"1","key":"832_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1600-0447.2011.01695.x","volume":"124","author":"JK Larsen","year":"2011","unstructured":"Larsen JK, Bendsen BB, Bech P. Vitamin B6 treatment of oedema induced by mirtazapine and isocarboxazid. Acta Psychiatr Scand. 2011;124(1):76\u20137.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"832_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/BF00165029","volume":"335","author":"HH Keller","year":"1987","unstructured":"Keller HH, et al. Short-acting novel mao inhibitors\u2014in vitro evidence for the reversibility of MAO inhibition by moclobemide and RO 16\u20136491. Naunyn-Schmiedebergs Arch Pharmacol. 1987;335(1):12\u201320.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"832_CR31","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1007\/BF02246225","volume":"106","author":"W Haefely","year":"1992","unstructured":"Haefely W, et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology. 1992;106(1):S6\u201314.","journal-title":"Psychopharmacology"},{"issue":"5","key":"832_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/BF02285092","volume":"43","author":"C Audebert","year":"1992","unstructured":"Audebert C, et al. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers. Eur J Clin Pharmacol. 1992;43(5):507\u201312.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"832_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1527-3458.2003.tb00245.x","volume":"9","author":"U Bonnet","year":"2003","unstructured":"Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003;9(1):97\u2013140.","journal-title":"CNS Drug Rev"},{"issue":"4","key":"832_CR34","doi-asserted-by":"publisher","first-page":"16S","DOI":"10.1097\/00004714-199508001-00004","volume":"15","author":"J Angst","year":"1995","unstructured":"Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol. 1995;15(4):16S-23S.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"832_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/YIC.0000000000000042","volume":"29","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, Green M, Montgomery SA. Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study. Int Clin Psychopharmacol. 2014;29(6):339\u201343.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"832_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0893-133X(98)00075-X","volume":"20","author":"F Lotufo-Neto","year":"1999","unstructured":"Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226\u201347.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"832_CR37","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S2215-0366(14)70329-3","volume":"1","author":"E Mayo-Wilson","year":"2014","unstructured":"Mayo-Wilson E, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):368\u201376.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"832_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00004714-200206000-00008","volume":"22","author":"E Uhlenhuth","year":"2002","unstructured":"Uhlenhuth E, Warner TD, Matuzas W. Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol. 2002;22(3):275\u201384.","journal-title":"J Clin Psychopharmacol"},{"key":"832_CR39","doi-asserted-by":"crossref","unstructured":"Philipp M, Tiller J, Baier D, For the the Australian and German Study Groups. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. Eur Neuropsychopharmacol. 2000;10(5):305\u201314.","DOI":"10.1016\/S0924-977X(00)00085-7"},{"issue":"1","key":"832_CR40","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1007\/BF02246229","volume":"106","author":"R Amrein","year":"1992","unstructured":"Amrein R, et al. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology. 1992;106(1):S24\u201331.","journal-title":"Psychopharmacology"},{"issue":"6872","key":"832_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/bmj.306.6872.248","volume":"306","author":"O Spigset","year":"1993","unstructured":"Spigset O, Mj\u00f6rndal T, L\u00f6vheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. Br Med J. 1993;306(6872):248.","journal-title":"Br Med J"},{"issue":"04","key":"832_CR42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1055\/s-2007-979565","volume":"29","author":"F Benazzi","year":"1996","unstructured":"Benazzi F. Serotonin syndrome with moclobemide-fluoxetine combination. Pharmacopsychiatry. 1996;29(04):162\u2013162.","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"832_CR43","doi-asserted-by":"publisher","first-page":"523","DOI":"10.5694\/j.1326-5377.1998.tb123399.x","volume":"169","author":"BS Chan","year":"1998","unstructured":"Chan BS, et al. Serotonin syndrome resulting from drug interactions. Med J Aust. 1998;169(10):523\u20135.","journal-title":"Med J Aust"},{"issue":"6","key":"832_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40263-015-0249-8","volume":"29","author":"D Robakis","year":"2015","unstructured":"Robakis D, Fahn S. Defining the role of the monoamine oxidase-B inhibitors for Parkinson\u2019s disease. CNS Drugs. 2015;29(6):433\u201341.","journal-title":"CNS Drugs"},{"issue":"6","key":"832_CR45","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1586\/17512433.2016.1093416","volume":"8","author":"AM Bied","year":"2015","unstructured":"Bied AM, Kim J, Schwartz TL. A critical appraisal of the selegiline transdermal system for major depressive disorder. Expert Rev Clin Pharmacol. 2015;8(6):673\u201381.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"832_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/01.jcp.0000239794.37073.70","volume":"26","author":"JD Amsterdam","year":"2006","unstructured":"Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26(6):579\u201386.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"832_CR47","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","volume":"159","author":"JA Bodkin","year":"2002","unstructured":"Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869\u201375.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"832_CR48","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.4088\/JCP.v67n0905","volume":"67","author":"AD Feiger","year":"2006","unstructured":"Feiger AD, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67(9):1354\u201361.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"832_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jad.2013.06.027","volume":"151","author":"L Citrome","year":"2013","unstructured":"Citrome L, Goldberg JF, Portland KB. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2013;151(2):409\u201317.","journal-title":"J Affect Disord"},{"key":"832_CR50","unstructured":"American Psychiatric Association. Desk reference to the diagnostic criteria from DSM-5\u2122. Arlington: American Psychiatric Publishing, Inc.; 2013."},{"issue":"1","key":"832_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.psychres.2005.07.012","volume":"141","author":"V Henkel","year":"2006","unstructured":"Henkel V, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006;141(1):89\u2013101.","journal-title":"Psychiatry Res"},{"issue":"1","key":"832_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00406-003-0400-2","volume":"253","author":"D Baldwin","year":"2003","unstructured":"Baldwin D, et al. Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci. 2003;253(1):22\u20138.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"832_CR53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1192\/bjp.bp.111.102665","volume":"201","author":"A Fekadu","year":"2012","unstructured":"Fekadu A, et al. Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry. 2012;201(5):369\u201375.","journal-title":"Br J Psychiatry"},{"key":"832_CR54","doi-asserted-by":"crossref","unstructured":"Suchting R, et al. Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: a systematic review and network meta-analysis. J Affect Disord. 2021;282:1153\u201360.","DOI":"10.1016\/j.jad.2021.01.021"},{"key":"832_CR55","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/00004850-199710006-00006","volume":"12","author":"J Tiller","year":"1997","unstructured":"Tiller J, Bouwer C, Behnke K. Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. Int Clin Psychopharmacol. 1997;12:S27-30.","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"832_CR56","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1017\/S003329171700349X","volume":"48","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2018;48(12):1975\u201384.","journal-title":"Psychol Med"},{"key":"832_CR57","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1192\/bjp.161.5.665","volume":"161","author":"J Vallejo","year":"1992","unstructured":"Vallejo J, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry. 1992;161:665\u201370.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"832_CR58","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archpsyc.1983.04390010015002","volume":"40","author":"TR Insel","year":"1983","unstructured":"Insel TR, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983;40(6):605\u201312.","journal-title":"Arch Gen Psychiatry"},{"key":"832_CR59","unstructured":"Jenike MA, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 1997."},{"key":"832_CR60","doi-asserted-by":"publisher","unstructured":"Grant JE, Baldwin DS, Chamberlain SR. Time to reconsider monoamine oxidase inhibitors for obsessive compulsive disorder? A case series using phenelzine. J Clin Psychopharmacol. 2021. https:\/\/doi.org\/10.1097\/JCP.0000000000001418","DOI":"10.1097\/JCP.0000000000001418"},{"key":"832_CR61","unstructured":"Himmelhoch JM, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991."},{"issue":"S6","key":"832_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1192\/S0007125000297535","volume":"155","author":"U Baumhackl","year":"1989","unstructured":"Baumhackl U, et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study. Br J Psychiatry. 1989;155(S6):78\u201383.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"832_CR63","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00131746-200407000-00005","volume":"10","author":"JG Fiedorowicz","year":"2004","unstructured":"Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. 2004;10(4):239\u201348.","journal-title":"J Psychiatr Pract"},{"issue":"4","key":"832_CR64","first-page":"533","volume":"13","author":"J Volpi-Abadie","year":"2013","unstructured":"Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533\u201340.","journal-title":"Ochsner J"},{"issue":"9","key":"832_CR65","first-page":"1139","volume":"81","author":"AZ Ables","year":"2010","unstructured":"Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. Am Fam Physician. 2010;81(9):1139\u201342.","journal-title":"Am Fam Physician"},{"issue":"3","key":"832_CR66","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/0006-3223(93)90384-P","volume":"34","author":"MR Lavin","year":"1993","unstructured":"Lavin MR, Mendelowitz A, Kronig MH. Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biol Psychiatry. 1993;34(3):146\u201351.","journal-title":"Biol Psychiatry"},{"issue":"11","key":"832_CR67","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00702-018-1932-y","volume":"125","author":"PK Gillman","year":"2018","unstructured":"Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm. 2018;125(11):1707\u201317.","journal-title":"J Neural Transm"},{"key":"832_CR68","doi-asserted-by":"publisher","unstructured":"Culpepper L. Reducing the burden of difficult-to-treat major depressive disorder: revisiting monoamine oxidase inhibitor therapy. Prim Care Compan CNS Disord. 2013;15(5):PCC.13r01515. https:\/\/doi.org\/10.4088\/PCC.13r01515.","DOI":"10.4088\/PCC.13r01515"},{"key":"832_CR69","unstructured":"Forrest J. What is the risk of interaction between opioids and monoamine oxidase inhibitors (MAOIs)? 2018. https:\/\/www.sps.nhs.uk\/articles\/what-is-the-risk-of-interaction-between-opioids-and-monoamine-oxidase-inhibitors-maois\/. Accessed 11 June 2021"},{"issue":"1","key":"832_CR70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1017\/S109285291200003X","volume":"17","author":"MM Grady","year":"2012","unstructured":"Grady MM, Stahl SM. Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS spectr. 2012;17(1):2\u201310.","journal-title":"CNS spectr"},{"key":"832_CR71","first-page":"605","volume-title":"The essentials of postgraduate psychiatry","author":"LS Pilowsky","year":"1997","unstructured":"Pilowsky LS, Kerwin RW. Biological treatments in psychiatry. In: Murray R, Hill P, McGuffin P, editors. The essentials of postgraduate psychiatry. Cambridge: Cambridge University Press; 1997. p. 605\u201334."},{"issue":"11","key":"832_CR72","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1176\/ajp.137.11.1422","volume":"137","author":"K White","year":"1980","unstructured":"White K, Pistole T, Boyd JL. Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. Am J Psychiatry. 1980;137(11):1422\u20135.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"832_CR73","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/phar.1576","volume":"35","author":"SJ Thomas","year":"2015","unstructured":"Thomas SJ, et al. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015;35(4):433\u201349.","journal-title":"Pharmacotherapy"},{"key":"832_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cbi.2015.01.028","volume":"230","author":"R Nirogi","year":"2015","unstructured":"Nirogi R, et al. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015;230:9\u201320.","journal-title":"Chem Biol Interact"},{"issue":"11","key":"832_CR75","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.euroneuro.2015.07.021","volume":"25","author":"L Bartova","year":"2015","unstructured":"Bartova L, et al. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases. Eur Neuropsychopharmacol. 2015;25(11):2183\u20134.","journal-title":"Eur Neuropsychopharmacol"},{"key":"832_CR76","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.genhosppsych.2018.05.007","volume":"54","author":"R Katz","year":"2018","unstructured":"Katz R, et al. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: a letter to the editor. Gen Hosp Psychiatry. 2018;54:62.","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"832_CR77","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/JCP.0000000000001244","volume":"40","author":"JCC Wang","year":"2020","unstructured":"Wang JCC, Swainson J. The concurrent treatment with intravenous ketamine and an irreversible monoamine oxidase inhibitor for treatment-resistant depression without hypertensive crises. J Clin Psychopharmacol. 2020;40(5):515\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"832_CR78","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fphar.2016.00340","volume":"7","author":"JP Finberg","year":"2016","unstructured":"Finberg JP, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol. 2016;7:340.","journal-title":"Front Pharmacol"},{"key":"832_CR79","doi-asserted-by":"crossref","unstructured":"Chiuccariello L. et al. Monoamine oxidase\u2014a occupancy by moclobemide and phenelzine: implications for the development of monoamine oxidase inhibitors. Int J Neuropsychopharmacol. 2016;19(1).","DOI":"10.1093\/ijnp\/pyv078"},{"key":"832_CR80","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/bmj.1.5439.881","volume":"1","author":"D Zangwill","year":"1965","unstructured":"Zangwill D. Clinical trial of the treatment of depressive illness. Br Med J. 1965;1:881\u20136.","journal-title":"Br Med J"},{"issue":"3","key":"832_CR81","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1192\/bjp.141.3.243","volume":"141","author":"ES Paykel","year":"1982","unstructured":"Paykel ES, et al. Influence of acetylator phenotype on antidepressant effects of phenelzine. Br J Psychiatry. 1982;141(3):243\u20138.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"832_CR82","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5694\/mja2.50522","volume":"212","author":"J Rothmore","year":"2020","unstructured":"Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020;212(7):329\u201334.","journal-title":"Med J Aust"},{"issue":"1","key":"832_CR83","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1461145705006358","volume":"10","author":"DS Baldwin","year":"2007","unstructured":"Baldwin DS, et al. Discontinuation symptoms in depression and anxiety disorder. Int J Neuropsychopharmacol. 2007;10(1):73\u201384.","journal-title":"Int J Neuropsychopharmacol"},{"key":"832_CR84","first-page":"269","volume":"1","author":"J Le Gassicke","year":"1963","unstructured":"Le Gassicke J. Tranylcypromine. Lancet. 1963;1:269\u201370.","journal-title":"Lancet"},{"issue":"3","key":"832_CR85","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1192\/bjp.135.3.273","volume":"135","author":"O Ben-Arie","year":"1979","unstructured":"Ben-Arie O, George G. A case of tranylcypromine (\u2018Parnate\u2019) addiction. Br J Psychiatry. 1979;135(3):273\u20134.","journal-title":"Br J Psychiatry"},{"issue":"5914","key":"832_CR86","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bmj.2.5914.332-d","volume":"2","author":"B Pitt","year":"1974","unstructured":"Pitt B. Withdrawal symptoms after stopping phenelzine? BMJ. 1974;2(5914):332.","journal-title":"BMJ"},{"issue":"1","key":"832_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-0327(84)90002-8","volume":"6","author":"P Tyrer","year":"1984","unstructured":"Tyrer P. Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. J Affect Disord. 1984;6(1):1\u20137.","journal-title":"J Affect Disord"},{"issue":"1","key":"832_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1988.tb06293.x","volume":"78","author":"SC Dilsaver","year":"1988","unstructured":"Dilsaver SC. Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatr Scand. 1988;78(1):1\u20137.","journal-title":"Acta Psychiatr Scand"},{"issue":"04","key":"832_CR89","first-page":"123","volume":"2","author":"M Gahr","year":"2013","unstructured":"Gahr M, et al. Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review. Pharmacopsychiatry. 2013;2(04):123\u20139.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"832_CR90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/026988110201600314","volume":"16","author":"F Curtin","year":"2002","unstructured":"Curtin F, Berney P, Kaufmann C. Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. J Psychopharmacol. 2002;16(3):271\u20132.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"832_CR91","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/molecules24030418","volume":"24","author":"P Dhiman","year":"2019","unstructured":"Dhiman P, et al. Quercetin and related chromenone derivatives as monoamine oxidase inhibitors: targeting neurological and mental disorders. Molecules. 2019;24(3):418.","journal-title":"Molecules"},{"issue":"5","key":"832_CR92","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/pharmaceutics12050410","volume":"12","author":"F Moreira-Silva","year":"2020","unstructured":"Moreira-Silva F, et al. Repurposing old drugs into new epigenetic inhibitors: promising candidates for cancer treatment? Pharmaceutics. 2020;12(5):410.","journal-title":"Pharmaceutics"},{"issue":"1","key":"832_CR93","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41391-020-0211-9","volume":"24","author":"ME Gross","year":"2021","unstructured":"Gross ME, et al. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(1):61\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"832_CR94","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41375-020-0892-z","volume":"35","author":"M Wass","year":"2021","unstructured":"Wass M, et al. A proof of concept phase I\/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory\/relapsed AML patients not eligible for intensive therapy. Leukemia. 2021;35(3):701\u201311.","journal-title":"Leukemia"},{"issue":"1\u20132","key":"832_CR95","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0161-813X(03)00102-5","volume":"25","author":"K Magyar","year":"2004","unstructured":"Magyar K, Szende B. (\u2212)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology. 2004;25(1\u20132):233-242.99.","journal-title":"Neurotoxicology"},{"key":"832_CR96","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology, 3rd edn. New York: 2008. Stahl Online. https:\/\/stahlonline.cambridge.org. Accessed 22 Apr 2021."},{"key":"832_CR97","unstructured":"Royal College of Psychiatrists Psychopharmacology Committee. Use of licensed medicines for unlicensed applications in psychiatric practice. 2nd edition. College Report CR210. London: Royal College of Psychiatrists; 2017. https:\/\/www.rcpsych.ac.uk\/improving-care\/campaigning-for-better-mental-health-policy\/college-reports\/2017-college-reports\/use-of-licensed-medicines-for-unlicensed-applications-in-psychiatric-practice-2nd-edition-cr210-dec-2017."}],"updated-by":[{"DOI":"10.1007\/s40263-021-00880-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00832-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:44:31Z","timestamp":1666770271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00832-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00832-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-021-00880-3","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"27 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-021-00880-3","URL":"https:\/\/doi.org\/10.1007\/s40263-021-00880-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Chamberlain\u2019s role in this paper was funded by a Clinical Fellowship from the Wellcome Trust (reference 110049\/Z\/15\/Z and 110049\/Z\/15\/A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Prof. Chamberlain previously consulted for Promentis on work not related to MAOIs. He also receives honoraria from Elsevier for editorial work at the journals <i>Neuroscience and Biobehavioral Reviews<\/i> and <i>Comprehensive Psychiatry<\/i>. Prof. Baldwin is President-Elect of the BAP and a medical patron of Anxiety UK. He also receives stipends from Wiley for editorial work relating to the journal <i>Human Psychopharmacology<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Professors Baldwin and Chamberlain were both involved in all aspects of manuscript development, from conception to submission.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}